CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- ARS Other Annual Report to Security Holders
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Planned sale Chief Scientific Officer sold 8,000 shares at $15.68 ($125,440)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Scientific Officer sold 1,780 shares at $14.14 ($25,169)
- 4 Planned sale Chief Scientific Officer sold 5,353 shares at an average $14.31 ($76,617)
- 4 Open-market sale President and CEO sold 13,515 shares at $14.47 ($195,562)
- 4 Open-market sale Chief Medical Officer sold 4,582 shares at $14.47 ($66,302)
- 4 Open-market sale Chief Legal Officer sold 3,601 shares at $14.47 ($52,106)
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Medical Officer sold 4,982 shares at $13.62 ($67,855)
- 4 Planned sale Chief Scientific Officer sold 11,742 shares at an average $14.08 ($165,366)
- 4 Open-market sale Chief Legal Officer sold 3,742 shares at $13.62 ($50,966)
- 4 Open-market sale President and CEO sold 16,381 shares at $13.62 ($223,109)
Page 3 of 24 · 471 filings